Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMLOPRIL is a fixed-dose combination pharmaceutical product containing amlodipine and lisinopril, developed and distributed by GoodMed Healthcare for the management of hypertension. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced blood pressure. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. By inhibiting ACE, lisinopril reduces peripheral vascular resistance and decreases aldosterone secretion, which promotes sodium and water excretion. The combination of these two mechanisms provides a synergistic effect in lowering blood pressure and is used when monotherapy is insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AMLOPRIL.